• Home
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Annual Report and Proxy
    • Special Meeting Proxy
  • Stock Information
  • Resources
    • Email Alerts
    • Contact

Blue Water Vaccines Announces Closing of $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 20, 2022 | Press Releases

Proceeds To Fund Research and Development of BWV-101, BWV-102 and BWV-103CINCINNATI, April 20, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing...

Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 13, 2022 | Press Releases

Proceeds To Fund Research and Development of BWV-101, BWV 102 and BWV-103.CINCINNATI, April 13, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing...

Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 13, 2022 | Press Releases

Proceeds To Fund Research and Development of BWV-101, BWV 102 and BWV-103.CINCINNATI, April 13, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing...

Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022

Apr 11, 2022 | Press Releases

BWV-101 – Universal Influenza Program: Developing a novel vaccine to protect against all influenza strains using groundbreaking mathematical models and research CINCINNATI, April 11, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water...

Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility

Mar 22, 2022 | Press Releases

Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform.The data supports BWV’s ongoing development of a transformational universal influenza...

Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility

Mar 22, 2022 | Press Releases

Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform.The data supports BWV’s ongoing development of a transformational universal influenza...
« Older Entries
Next Entries »

Recent Posts

  • Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement
  • Onconetix Announces Reverse Stock Split
  • Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
  • CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
  • Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Recent Comments

No comments to show.

Stay up to date

Keep informed on investor news & updates

© 2026 Onconetix